Archive · 22 Sep 2026
Kotak Upgrades Mankind Pharma as Domestic Business Recovery Emerges
Kotak Institutional Equities changed its view of Mankind Pharma’s shares to a more positive one.
This is called an upgrade.
The research firm believes the company’s main domestic business is beginning to recover.
It said this recovery is now clearly visible.
The business had previously been affected by a long restructuring period.
Kotak’s view helped support the upgrade.
The article also says Mankind Pharma’s price target is among the top five on the street.
The exact price target was not provided.
Kotak Institutional Equities upgraded Mankind Pharma’s shares.
The upgrade is partly based on recovery in the company’s domestic business.
Kotak said the domestic business is showing tangible recovery signs.
The recovery follows a prolonged period affected by restructuring.
Mankind Pharma’s price target is described as among the top five on the street.
- Who
- Kotak Institutional Equities and Mankind Pharma.
- What
- Kotak Institutional Equities upgraded its view of Mankind Pharma shares.
- Why
- Kotak said Mankind Pharma’s domestic business is showing tangible signs of recovery after a prolonged restructuring impact.
- Company
- Mankind Pharma
- Analyst
- Kotak Institutional Equities
- Action
- Share upgrade
- Recovery area
- Domestic business
- Previous challenge
- Prolonged restructuring impact
- Price-target ranking
- Among the top five on the street